Given light of implications of Microsatellite Instability (MSI) as a pan-cancer therapeutic marker, this presentation outlines the approach to its testing and considerations for providing MSI testing in a clinical setting. 

This presentation highlights how immuno-oncology testing is developed, explanation of output and its implications to the patient. You will explore the current state of mutational burden in trials and considerations for using this across different sized genomic tests, such as RNA sequencing for immune response.

Plus, you will have the opportunity to dive deeper into B/T-Cell repertoire testing, its current impact in clinical trials, use in biomarker discovery and implications to interpretation.

Authors:
Victor Weigman, Ph.D., Director, Translational Genomics
Jennifer Sims